FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D	D.C. 20549
---------------	------------

Check this box if no longer subject to	STATEMENT OF
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	Filed pursuant t

CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* SEVERINO MICHAEL						2. Issuer Name and Ticker or Trading Symbol AbbVie Inc. [ABBV]									ck all applic Directo	cable) r	g Perso	on(s) to Issu	ner
(Last) 1 N. WA	nst) (First) (Middle) N. WAUKEGAN ROAD					Date 0 /02/2	of Earliest 2014	Transa	action (Mo	nth/[Day/Year)		below)	(give title EVP, R&I	Other (s below) D and CSO		респу		
(Street) NORTH CHICAC	GO IL		60064		4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S	tate)	(Zip)			1 03011													
		Tab	le I - Nor	n-Deriv	vativ	e Se	curities	s Acq	uired, I	Disp	posed o	f, or B	ene	ficiall	y Owned				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					Exe Day/Year) if a		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8) 4. Security Disposed 5)						es ally Following	Form:	: Direct Control of the control of t	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	it (A) or (D)		Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Common stock, \$0.01 par value 06/02/					2/201	/2014		A		141,62	41,625 ⁽¹⁾ A		\$ <mark>0</mark>	141,625			D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution I if any (Month/Day	Date,	4. Transa Code (l 8)		of		6. Date Exe Expiration (Month/Da	Date	of Securities		curity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)		Date Exercisabl		Expiration Date	Title	or No of	umber					
Option (right to buy) ⁽²⁾	\$54.44	06/02/2014			A		74,309		06/02/201	5 0	6/01/2024	Commo stock	ⁿ 7	4,309	\$0	74,309		D	

Explanation of Responses:

- 1. This stock represents performance vested restricted stock under the AbbVie 2013 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon AbbVie reaching a minimum return on equity target. The awards include the right to have a stock withheld for tax purposes
- 2. Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 24,770 on 06/02/2015, 24,769 on 06/02/2016, and 24,770 on 06/02/2017.

Steven L. Scrogham, attorneyin-fact for Michael Severino

06/04/2014

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.